Gerhardt Attard

35.0k total citations · 4 hit papers
248 papers, 11.5k citations indexed

About

Gerhardt Attard is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Gerhardt Attard has authored 248 papers receiving a total of 11.5k indexed citations (citations by other indexed papers that have themselves been cited), including 215 papers in Pulmonary and Respiratory Medicine, 95 papers in Cancer Research and 89 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Gerhardt Attard's work include Prostate Cancer Treatment and Research (203 papers), Radiopharmaceutical Chemistry and Applications (78 papers) and Prostate Cancer Diagnosis and Treatment (50 papers). Gerhardt Attard is often cited by papers focused on Prostate Cancer Treatment and Research (203 papers), Radiopharmaceutical Chemistry and Applications (78 papers) and Prostate Cancer Diagnosis and Treatment (50 papers). Gerhardt Attard collaborates with scholars based in United Kingdom, United States and Canada. Gerhardt Attard's co-authors include Johann S. de Bono, Alison Reid, Roberta Ferraldeschi, Chris Parker, David Olmos, Carmel Pezaro, David P. Dearnaley, Stan B. Kaye, Colin S. Cooper and Ian F. Tannock and has published in prestigious journals such as The Lancet, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Gerhardt Attard

238 papers receiving 11.3k citations

Hit Papers

Prostate cancer 2008 2026 2014 2020 2015 2008 2022 2022 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Prostate cancer
    2015 708 citations Gerhardt Attard, Johann S. de Bono et al. profile →
  2. Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven
    2008 666 citations Gerhardt Attard, Alison Reid et al. Journal of Clinical Oncology profile →
  3. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group
    2022 355 citations Gerhardt Attard et al. Annals of Oncology profile →
  4. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol
    2022 191 citations Gerhardt Attard profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gerhardt Attard United Kingdom 56 8.1k 4.4k 3.6k 3.3k 2.0k 248 11.5k
Mary‐Ellen Taplin United States 34 8.2k 1.0× 2.6k 0.6× 2.6k 0.7× 2.2k 0.7× 2.1k 1.0× 203 9.9k
David Olmos United Kingdom 48 6.3k 0.8× 3.2k 0.7× 3.2k 0.9× 4.1k 1.2× 1.4k 0.7× 233 10.4k
Andrew J. Armstrong United States 52 11.0k 1.4× 4.5k 1.0× 3.8k 1.1× 5.0k 1.5× 3.5k 1.7× 426 14.6k
Thian Kheoh United States 38 6.2k 0.8× 2.4k 0.5× 1.3k 0.4× 2.3k 0.7× 2.3k 1.1× 124 7.6k
John Wongvipat United States 23 5.1k 0.6× 2.0k 0.4× 3.3k 0.9× 1.6k 0.5× 985 0.5× 35 7.4k
Eleni Efstathiou United States 41 4.7k 0.6× 1.7k 0.4× 2.0k 0.6× 2.4k 0.7× 1.3k 0.6× 203 7.4k
Jun Luo United States 50 5.7k 0.7× 3.3k 0.7× 4.6k 1.3× 1.7k 0.5× 695 0.3× 146 9.4k
B. Yа. Alekseev Russia 32 5.4k 0.7× 2.3k 0.5× 2.2k 0.6× 2.2k 0.7× 1.5k 0.7× 316 7.7k
Daniel C. Danila United States 34 4.0k 0.5× 2.8k 0.6× 1.9k 0.5× 2.5k 0.8× 948 0.5× 130 6.6k
Glenn Liu United States 46 4.9k 0.6× 1.8k 0.4× 2.5k 0.7× 2.8k 0.9× 2.0k 1.0× 175 8.5k

Countries citing papers authored by Gerhardt Attard

Since Specialization
Citations

This map shows the geographic impact of Gerhardt Attard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerhardt Attard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerhardt Attard more than expected).

Fields of papers citing papers by Gerhardt Attard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gerhardt Attard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerhardt Attard. The network helps show where Gerhardt Attard may publish in the future.

Co-authorship network of co-authors of Gerhardt Attard

This figure shows the co-authorship network connecting the top 25 collaborators of Gerhardt Attard. A scholar is included among the top collaborators of Gerhardt Attard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gerhardt Attard. Gerhardt Attard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
4.
5.
Linch, Mark, Gianmarco Leone, Yien Ning Sophia Wong, et al.. (2024). Nivolumab and ipilimumab for metastatic prostate cancer with an immunogenic signature: The NEPTUNES multi-centre two-cohort, biomarker-selected phase 2 trial.. Journal of Clinical Oncology. 42(16_suppl). 5013–5013. 5 indexed citations
6.
7.
Sutera, Philip, Amol C. Shetty, Yang Song, et al.. (2023). Identification of a Predictive Genomic Biomarker for Prostate-directed Therapy in Synchronous Low-volume Metastatic Castration-sensitive Prostate Cancer. European Urology Oncology. 7(2). 241–247. 6 indexed citations
8.
9.
10.
11.
Sutera, Philip, Amol C. Shetty, Yang Song, et al.. (2023). Identification of a Predictive Genomic Biomarker for Prostate Directed Therapy in Synchronous Low-Volume Metastatic Castration Sensitive Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics. 117(2). e441–e442.
12.
Posadas, Edwin M., Kim N., Ronald de Wit, et al.. (2020). Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study. Clinical Cancer Research. 26(14). 3517–3524. 12 indexed citations
13.
Conteduca, Vincenza, Daniel Wetterskog, Emanuela Scarpi, et al.. (2020). Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer. British Journal of Cancer. 123(6). 982–987. 27 indexed citations
14.
Scher, Howard I., Glenn Heller, Arturo Molina, et al.. (2015). Circulating Tumor Cell Biomarker Panel As an Individual-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology. 33(12). 1348–1355. 294 indexed citations
15.
Attard, Gerhardt, Johann S. de Bono, Christopher J. Logothetis, et al.. (2015). Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate. Clinical Cancer Research. 21(7). 1621–1627. 39 indexed citations
16.
Carden, Craig P., Adam Stewart, Emma Kipps, et al.. (2012). The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer. Molecular Cancer Therapeutics. 11(7). 1609–1617. 81 indexed citations
17.
Hay, C. R. M., Angela E. Taylor, Anna Wingate, et al.. (2012). Interactions of Abiraterone, Eplerenone, and Prednisolone with Wild-type and Mutant Androgen Receptor: A Rationale for Increasing Abiraterone Exposure or Combining with MDV3100. Cancer Research. 72(9). 2176–2182. 201 indexed citations
18.
Olmos, David, Richard D. Baird, Timothy A. Yap, et al.. (2011). Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials. Clinical Cancer Research. 17(15). 5188–5196. 21 indexed citations
19.
Attard, Gerhardt, Alison Reid, Timothy A. Yap, et al.. (2008). Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven. Journal of Clinical Oncology. 26(28). 4563–4571. 666 indexed citations breakdown →
20.
Plummer, Ruth, Gerhardt Attard, Simon Pacey, et al.. (2007). Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers. Clinical Cancer Research. 13(20). 6187–6194. 198 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mary‐Ellen Taplin Breakdown of academic impact, for papers by David Olmos Breakdown of academic impact, for papers by Andrew J. Armstrong Breakdown of academic impact, for papers by Thian Kheoh Breakdown of academic impact, for papers by John Wongvipat Breakdown of academic impact, for papers by Eleni Efstathiou Breakdown of academic impact, for papers by Jun Luo Breakdown of academic impact, for papers by B. Yа. Alekseev Breakdown of academic impact, for papers by Daniel C. Danila Breakdown of academic impact, for papers by Glenn Liu
Rankless by CCL
2026